Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia

References

• Grimwade D. The pathogenesis of acute promyelocytic leukemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease. Br J Haematol. 1999;106:591–613.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Nabhan C, Feusner JH, et al. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759–767.
   PubMed Web of Science ®Google Scholar
• Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative groups. Blood. 1997;90:1014–1021.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1201–1208.
   Web of Science ®Google Scholar
• Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993;82:3241–3249.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93:4131–4143.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: a multicentre study by the PETHEMA group. Blood. 2004;103:1237–1243.
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171–3179.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Lo Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29:495–503.
   PubMed Web of Science ®Google Scholar
• Zhang TD, Chen GQ, Wang ZG, et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene. 2001;20:7146–7153.
   PubMed Web of Science ®Google Scholar
• Litzow MR. Arsenic trioxide. Expert Opin Pharmacother. 2008;9:1773–1785.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–2515.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 2. J Nat Compr Cancer Netw. 2013;11:1047–1055.
   PubMed Web of Science ®Google Scholar
• Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. J Biol Inorg Chem. 2018;23:313–329.
   PubMed Web of Science ®Google Scholar
• Fukai Y, Hirata M, Ueno M, et al. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull. 2006;29:1022–1027.
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Fong BM, et al. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008;112:3587–3590.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl2 expression and modulation of PML-RARa/Pml proteins. Blood. 1996;88:1052–1061.
   PubMed Web of Science ®Google Scholar
• Nasr R, Lallemand-Breitenbach V, Zhu J, et al. Therapy-induced PML/RARa proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res. 2009;15:6321–6326.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML/RARalpha oncoprotein by directly binding PML. Science. 2010;328:240–243.
   PubMed Web of Science ®Google Scholar
• Costantini P, Belzacq AS, Vieira HL, et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2 independent permeability transition pore opening and apoptosis. Oncogene. 2000;19:307–314.
   PubMed Web of Science ®Google Scholar
• Li J, Chen P, Sinogeeva N, et al. Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells. J Biol Chem. 2002;277:49504–49510.
   PubMed Web of Science ®Google Scholar
• Davison K, Mann KK, Miller WH Jr, et al. Arsenic trioxide: mechanisms of action. Semin Hematol. 2002;39:3–7.
   PubMed Web of Science ®Google Scholar
• Bernardini S, Nuccettelli M, Noguera NI, et al. Role of GSTP-1 in mediating the effect of As2O3 in the acute promyelocytic leukemia cell line NB4. Ann Hematol. 2006;85:681–687.
   PubMed Web of Science ®Google Scholar
• Ninomiya M, Kajiguchi T, Yamamoto K, et al. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica. 2006;91:1571–1572.
   PubMed Web of Science ®Google Scholar
• Chou WC, Chen HY, Yu SL, et al. Arsenic suppresses gene expression in promyelocytic leukemia cells partly troughSp1 oxidation. Blood. 2005;106:304–310.
   PubMed Web of Science ®Google Scholar
• Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Ann NY Acad Sci. 2006;1090:203–208.
   PubMed Web of Science ®Google Scholar
• Glienke W, Chow KU, Bauer N, et al. Down-regulation of Wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma. 2006;47:1629–1638.
   PubMed Web of Science ®Google Scholar
• Zheng PZ, Wang KK, Zhang QY, et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation7apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA. 2005;102:7653.
   PubMed Web of Science ®Google Scholar
• Ghaffari SH, Bashash D, Dizaji MZ, et al. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action. Tumour Biol. 2012;33:157–172.
   PubMedGoogle Scholar
• Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101:5328–5335.
   PubMed Web of Science ®Google Scholar
• Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106:3342–3347.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–2632.
   PubMed Web of Science ®Google Scholar
• Mathews V, Thomas M, Srivastava VM, et al. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994–995.
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia. Long-term follow-up data. J Clin Oncol. 2010;28:3866–3871.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131–134.
   PubMed Web of Science ®Google Scholar
• Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29:2753–2757.
   PubMed Web of Science ®Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–3473.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans retinoic acid, arsenic trioxide, and gentuzumab ozogamicin. J Clin Oncol. 2009;27:504–510.
   PubMed Web of Science ®Google Scholar
• Dai CW, Zhang GS, Shen JK, et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol. 2009;121:1–8.
   PubMed Web of Science ®Google Scholar
• Illand HJ, Bradstock K, Supple SG, et al. All-trans retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570–1580.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukemia in the Australasian Leukmeia and Lymphoma Group (ALLG) APML4 study: a non randomized phase 2 trial. Lancet Hematol. 2015;2:e357–e366.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z, Li J, et al. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2013;119:115–125.
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–121.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35:605–612.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295–1305.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–1134.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118:1248–1254.
   PubMed Web of Science ®Google Scholar
• McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–136.
   PubMed Web of Science ®Google Scholar
• Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166:660–666.
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Ottone T, Divona M, et al. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukemia. Br J Haematol. 2016;172:909–913.
   PubMed Web of Science ®Google Scholar
• Cicconi L, Fenaux P, Kantarjian H, et al. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19:871–879.
   PubMed Web of Science ®Google Scholar